{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:09:05Z","timestamp":1788408545574,"version":"build-2803163510"},"reference-count":65,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2011,1,4]],"date-time":"2011-01-04T00:00:00Z","timestamp":1294099200000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[2011,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatorenal syndrome (HRS) is the most frequent life threatening complication of advanced liver failure and cirrhosis. HRS results from a functional renal dysfunction due to circulatory disturbances in patients with advanced liver disease and portal hypertension. Reduction in the effective circulating blood volume and hence hypoperfusion of the kidney is the basic underlying common pathogenetic mechanism for the development of hepatorenal syndrome. The prognosis for HRS remains very poor with types 1 and 2\u2014both having an expected survival time of 2\u2003weeks and 6\u2003months, respectively.<\/jats:p><jats:p>Although the available data are derived from studies including a limited number of patients mainly affected by type 1 HRS, vasoconstrictor drugs, in particular the vasopressin analog Terlipressin, seem to be the most effective approach for the management of HRS. Associated with albumin infusion, these drugs have been shown to lead to reduced mortality and improved renal function in HRS. Terlipressin administration significantly increases mean arterial pressure and systemic vascular resistance; while the heart rate, cardiac output, HVPG and portal venous blood flow decrease significantly. This decrease correlates well with the decrease in plasma renin activity. Thus the vasoconstrictor effect of Terlipressin reverses the basic pathology of HRS by reducing the plasma renin activity. The improvement in hemodynamics with Terlipressin is associated with an increase in glomerular filtration rate and deactivation of the vasoconstrictor and sodium\u2010conserving hormones with reduced activity of the RAAS resulting in increased natriuresis.<\/jats:p><jats:p>Terlipressin thus reverses HRS and is useful in bridging the patient to liver transplantation and may hence indirectly improve survival. Patients with HRS who show an improvement in renal function with Terlipressin and albumin seem to have an excellent post\u2010transplantation outcome similar to that of patients without HRS. Thus, the use of Terlipressin has been shown to be safe, with minimal side effects that usually disappear after dose reduction, and results in an improved outcome in patients with HRS.<\/jats:p>","DOI":"10.1111\/j.1440-1746.2010.06583.x","type":"journal-article","created":{"date-parts":[[2011,1,4]],"date-time":"2011-01-04T12:16:32Z","timestamp":1294143392000},"page":"109-114","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Terlipressin in hepatorenal syndrome: Evidence for present indications"],"prefix":"10.1111","volume":"26","author":[{"given":"Harshal","family":"Rajekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,1,4]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(56)90149-0"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2007.04.027"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.08.007"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.06.065"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199909000-00004"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-006-9099-z"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510230122"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.02.001"},{"key":"e_1_2_5_10_2","first-page":"1310","article-title":"Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis","volume":"56","author":"Salerno F","year":"2007","journal-title":"Gut."},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.08.004"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20066"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20262"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.34343"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840060216"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20687"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-10-200605160-00007"},{"key":"e_1_2_5_18_2","first-page":"474A","article-title":"High prevalence of glomerulonephritis in patients with end\u2010stage HCV\u2010induced cirrhosis","volume":"46","author":"McGuire B","year":"2007","journal-title":"Hepatology."},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01340406"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20766"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50447"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(70)80074-2"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.1983.tb00100.x"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(86)80154-4"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840170112"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20832"},{"key":"e_1_2_5_27_2","first-page":"CD005162","article-title":"Terlipressin for hepatorenal syndrome","volume":"4","author":"Gluud L","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03303.x"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.04.010"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2003.09.019"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(07)61680-8"},{"key":"e_1_2_5_32_2","first-page":"449A","article-title":"Noradrenaline versus Terlipressin in the treatment of type 1 hepatorenal syndrome: a randomized controlled trial","volume":"44","author":"Sharma P","year":"2006","journal-title":"Hepatology."},{"key":"e_1_2_5_33_2","first-page":"694A","article-title":"A prospective randomized double blind placebo\u2010controlled trial of Terlipressin for type 1 hepatorenal syndrome","volume":"44","author":"Sanyal A","year":"2006","journal-title":"Hepatology."},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0676.2000.020001051.x"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.1975.tb02283.x"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2009.05873.x"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e32833a4822"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21901"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1994.2150"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365520310008728"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(97)80456-4"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00053.2006"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1990.70.4.1067"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198212163072504"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2990050"},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2009.06132.x"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23286"},{"key":"e_1_2_5_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03086.x"},{"key":"e_1_2_5_49_2","first-page":"CD005162","article-title":"Terlipressin for hepatorenal syndrome","volume":"4","author":"Gluud LL","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_2_5_50_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.02.014"},{"key":"e_1_2_5_51_2","first-page":"564A","article-title":"Prognostic factors for hepatorenal syndrome (HRS) reversal in patients with type 1 HRS enrolled in a randomized double blind placebo controlled trial","volume":"46","author":"Sanyal A","year":"2007","journal-title":"Hepatology."},{"key":"e_1_2_5_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1665-2681(19)31767-3"},{"key":"e_1_2_5_53_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.03.064"},{"key":"e_1_2_5_54_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2002.02816.x"},{"key":"e_1_2_5_55_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.32364"},{"key":"e_1_2_5_56_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23283"},{"key":"e_1_2_5_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)80158-0"},{"key":"e_1_2_5_58_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.35819"},{"key":"e_1_2_5_59_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-007-9919-9"},{"key":"e_1_2_5_60_2","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e3283345524"},{"key":"e_1_2_5_61_2","unstructured":"KeavenyA Garcia\u2010TsaoG BexonAet\u2003al.Early indicators of outcome in type 1 hepatorenal syndrome: focus on serum creatinine in the pivotal Terlipressin Trial. The American Transplant Congress May 30\u2013June 3 2009 Boston MA USA."},{"key":"e_1_2_5_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2010.08.001"},{"key":"e_1_2_5_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(05)80042-X"},{"key":"e_1_2_5_64_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200212000-00013"},{"key":"e_1_2_5_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.03214.x"},{"key":"e_1_2_5_66_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510290629"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1746.2010.06583.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1746.2010.06583.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T17:57:16Z","timestamp":1694541436000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1746.2010.06583.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":65,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["10.1111\/j.1440-1746.2010.06583.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1746.2010.06583.x","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"2011-01-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}